BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20479550)

  • 1. Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection.
    Wernicke AG; Sherr DL; Schwartz TH; Pannullo SC; Stieg PE; Boockvar JA; Ivanidze J; Moliterno JA; Parashar B; Trichter S; Sabbas AM; Nori D
    J Cancer Res Ther; 2010; 6(1):65-74. PubMed ID: 20479550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study.
    Wernicke AG; Sherr DL; Schwartz TH; Pannullo SC; Stieg PE; Boockvar JA; Moliterno JA; Ivanidze J; Trichter S; Sabbas AM; Parashar B; Nori D
    Brachytherapy; 2010; 9(1):91-9. PubMed ID: 19850535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
    Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence.
    Kleinberg L; Yoon G; Weingart JD; Parisi M; Olivi A; Detorie NA; Chan TA
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1385-91. PubMed ID: 19394153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.
    Gabayan AJ; Green SB; Sanan A; Jenrette J; Schultz C; Papagikos M; Tatter SP; Patel A; Amin P; Lustig R; Bastin KT; Watson G; Burri S; Stea B
    Neurosurgery; 2006 Apr; 58(4):701-9; discussion 701-9. PubMed ID: 16575334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Chen AM; Chang S; Pouliot J; Sneed PK; Prados MD; Lamborn KR; Malec MK; McDermott MW; Berger MS; Larson DA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):825-30. PubMed ID: 17512132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
    Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential external beam radiotherapy and high-dose-rate intracavitary brachytherapy in T1 and T2 nasopharyngeal carcinoma: an evaluation of long-term outcome.
    Thiagarajan A; Lin K; Tiong CE; Tan LK; Loh TK; Goh BC; Lu JJ
    Laryngoscope; 2006 Jun; 116(6):938-43. PubMed ID: 16735885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.
    Niehoff P; Dietrich J; Ostertag H; Schmid A; Kohr P; Kimmig B; Kovács G
    Strahlenther Onkol; 2006 Feb; 182(2):102-7. PubMed ID: 16447017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
    Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
    Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
    Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
    Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?
    Yu E; Dar R; Rodrigues GB; Stitt L; Videtic GM; Truong P; Tomiak A; Ash R; Brecevic E; Inculet R; Malthaner R; Vincent M; Craig I; Kocha W; Lefcoe M
    Radiother Oncol; 2004 Nov; 73(2):141-8. PubMed ID: 15542160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.